Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Rezolsta

REZOLSTA 800 mg/150 mg film-coated tablets REZOLSTA 675 mg/150 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 16–17

HOS-220484 · Präparat HOS-216626

16 IMMUNOSUPPRESSANTS Ciclosporin Based on theoretical Therapeutic drug monitoring of Sirolimus considerations REZOLSTA is the immunosuppressive agent Tacrolimus expected to increase these must be done when immunosuppressant plasma co-administration occurs. concentrations. (CYP3A inhibition) Everolimus Concomitant use of everolimus and REZOLSTA is not recommended. INHALED BETA AGONISTS Salmeterol Based on theoretical Concomitant use of salmeterol considerations REZOLSTA is and REZOLSTA is not expected to increase salmeterol recommended. The combination plasma concentrations. may result in increased risk of (CYP3A inhibition) cardiovascular adverse event with salmeterol, including QT prolongation, palpitations and sinus tachycardia. NARCOTIC ANALGESICS/TREATMENT OF OPIOID DEPENDENCE Buprenorphine/naloxone Based on theoretical Dose adjustment for considerations REZOLSTA may buprenorphine may not be increase buprenorphine and/or necessary when co-administered norbuprenorphine plasma with REZOLSTA but a careful concentrations. clinical monitoring for signs of opiate toxicity is recommended. Methadone Based on theoretical No adjustment of methadone considerations REZOLSTA may dosage is expected when increase methadone plasma initiating co-administration with concentrations. REZOLSTA. Clinical monitoring is recommended, as maintenance With ritonavir-boosted darunavir, therapy may need to be adjusted a small decrease in methadone in some patients. plasma concentrations was observed. Consult the Summary of Product Characteristics for darunavir for further details. Fentanyl Based on theoretical Clinical monitoring is Oxycodone considerations REZOLSTA may recommended when Tramadol increase plasma concentrations of co-administering REZOLSTA these analgesics. with these analgesics. (CYP2D6 and/or CYP3A inhibition) OESTROGEN-BASED CONTRACEPTIVES Drospirenone (3 mg once daily) drospirenone AUC ↑ 58% Alternative or additional drospirenone Cmax ↑ 15% contraceptive measures are drospirenone Cmin ND recommended when oestrogen based contraceptives are co Ethinylestradiol (0.02 mg once ethinylestradiol AUC ↓ 30% administered with REZOLSTA. daily) ethinylestradiol Cmax ↓ 14% Patients using oestrogens as ethinylestradiol Cmin ND hormone replacement therapy should be clinically monitored for Norethindrone Based on theoretical signs of oestrogen deficiency. considerations REZOLSTA may When REZOLSTA is alter norethindrone plasma co-administered with a concentrations. drospirenone-containing product, (CYP3A inhibition, UGT/SULT clinical monitoring is induction) recommended due to the potential for hyperkalaemia.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): methadone (HOS-086198) oxycodone (HOS-109487) buprenorphine (HOS-086193) drospirenone (HOS-116422) salmeterol (HOS-086285) tacrolimus (HOS-085202) everolimus (HOS-086310) naloxone (HOS-109490) norethindrone (HOS-088136) sirolimus (HOS-085172) fentanyl (HOS-086196) tramadol (HOS-112871)